HSP90B1 and COVID-19: Both nonsevere (822.2 ± 208.8) and severe (1,048.0 ± 162.4) COVID-19 patients exhibited higher plasma gp96 levels than non-COVID-19 patients (553.4 ± 228.7) (P < 0.002).